No Data
Hong Kong stocks movement | Hutchmed (China) (00013) is currently down over 4%, with revenue for 2024 slightly below expectations. Institutions state that the revenue target for the fiscal year 2025 is conservative.
Hutchmed (China) (00013) is currently down over 4%, as of the time of writing, down 4.59%, at HKD 22.85, with a trading volume of 57.2795 million HKD.
HAITONG INT'L: Assigning Hutchmed (China) (00013) an "Outperform" rating with a Target Price of 46.66 HKD.
Management expects that 1-2 ATTC pipelines will enter the clinical stage in the second half of 2025.
Workday's Education Platform Becomes More Competitive Due to Recent Improvements: Needham
Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment
The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.
① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?
Hutchmed (China) Wins Conditional Approval for Lymphoma Treatment
Unlock the Full List
